Economic evaluation studies in health;Estudios de evaluación económica en salud

Medicina Clinica

Volumn 125, Issue SUPPL. 1, 2005, Pages 61-71

  Rovira Forns, Joan ^a   Antoñanzas Villar, Fernando ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NONE

Author keywords

Biases; Economic evaluations; Publication guidelines; Validity

Indexed keywords

ARTICLE; CLINICAL RESEARCH; ECONOMIC EVALUATION; HEALTH CARE; HEALTH ECONOMICS; HEALTH PROGRAM; MEDICAL LITERATURE; PUBLICATION;

AUTHORSHIP; CHECKLIST; CONSENSUS; DELIVERY OF HEALTH CARE; EVALUATION STUDIES AS TOPIC; GREAT BRITAIN; GUIDELINES AS TOPIC; PEER REVIEW; PERIODICALS AS TOPIC; PUBLISHING; QUALITY CONTROL; SPAIN;

EID: 34547802192     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13076481     Document Type: Article

References (42)

1. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275-83.
2. Martinson BC, Anderson MS, De Vries R. Scientists behaving badly. Nature. 2005;435:737-8.
3. Drummond MF. Economic evaluation of pharmaceuticals: science or marketing? Pharmacoeconomics. 1992;1:8-13.
4. Barbieri M, Drummond MF. Conflict of interest in industry-sponsored economic evaluations: real or imagined? Curr Oncol Rep. 2001;3:410-3.
5. Sacristán JA, Bolaños E, Hernández JM, Soto J, Galende I. Publication bias in health economics. Pharmacoeconomics. 1997;11:289-91.
6. Azimi NA, Welsh G. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med. 1998;13:664-9.
7. Friedberg M, Saffran B, Stinson, TJ Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282:1453-7.
8. Drummond MF, Cooke J, Walley T. Economic evaluation under managed competition: evidence from UK. Soc Sci Med. 1997;45:583-95.
9. Antoñanzas F, Figueras M, Rovira J. Analysing the Role of Economic Evaluation on Decision-Making in the Health Care System in Spain: A Focus Group Approach. En: Gran von der Schulenburg JM, editor. The Influence of Economic Evaluation Studies on Health Care Decision Making. Amsterdam: IOS Press; 2000.
10. Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, Kinosian B, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med. 1991;324:1362-5.
11. Task Force on Principles for Economic Analysis of. Economic analysis of health care technology: A report on principles. Ann Intern Med. 1995;123:61-70.
12. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analysis. N Engl J Med. 1994;331:669-70.
13. Drummond M, Brandt A, Luce B, Rovira J. Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care. 1993;9:26-36.
14. Rovira J. Economic appraisal of health technology in the European Community. Soc Sci Med. 1994;38:1675-8.
15. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Canberra: Australian Government Publishing Service; 1995.
16. Henry D. Economic analysis as an aid to subsidization decisions: the development of Australian guidelines for pharmaceuticals. Pharmacoeconomics. 1992;1:54-67.
17. Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Ontario: Ministry of Health; 1994.
18. Detsky A. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics. 1993;3:354-61.
19. Jacobs P, Bachynsky J, Baladi JF. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics. 1995;8:182-9.
20. Sculpher M, Claxton K. The use of economic evaluation for decision making: methodological opportunities and challenges [presentación]. International Health Economics Association Meeting, Barcelona: Julio 2005. http://www.york.ac.uk/inst/che/sculpher.htm
21. Maynard A. Economics evaluation techniques in health care: reinventing the wheel? Pharmacoeconomics. 1997;11:115-8.
22. Jefferson T, Smith R, Yee Y, Drummond M, Pratt M, Gale R. Evaluating the BMJ Guidelines for Economic Submissions: Prospective Audit of Economic Submissions to BMJ and The Lancet. JAMA. 1998;280:275-7.
23. Antoñanzas F. Artículos de evaluación económica en Gaceta Sanitaria: algunas reflexiones. Gac Sanit. 2003;17:351-2.
24. Sacristán JA, Ortún V, Rovira J, Prieto L, García-Alonso F, grupo ECOMED. Evaluación económica en medicina. Med Clin (Barc). 2004;122:379-82.
25. Prieto L, Sacristán JA, Pinto JL, Badía X, Antoñanzas F, del Llano J. Análisis de costes y resultados en la evaluación económica de las intervenciones sanitarias. Med Clin (Barc). 2004;122:423-9.
26. Prieto L, Sacristán JA, Antoñanzas F, Rubio-Terrés C, Pinto JL, Rovira J, grupo ECOMED. Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias. Med Clin (Barc). 2004;122:505-10.
27. Rubio-Terrés C, Sacristán JA, Badía X, Cobo E, García Alonso F, por el grupo ECOMED. Métodos utilizados para realizar evaluaciones económicas de intervenciones sanitarias. Med Clin (Barc). 2004;122:578-83.
28. Rubio-Terrés C, Cobo E, Sacristán JA, Prieto L, del Llano J, Badia X, García-Alonso F. Análisis de la incertidumbre en las evaluaciones económicas de las intervenciones sanitarias. Med Clin (Barc). 2004;122:668-74.
29. Sacristán JA, Rovira J, Ortún V, García-Alonso F, Prieto L, Antoñanzas F, grupo ECOMED. Utilización de las evaluaciones económicas de intervenciones sanitarias. Med Clin (Barc). 2004;122:789-95.
30. Bos JM, Postma MJ, Annemans L. Discounting health effects in Pharmacoeconomic evaluations: Current controversies. Pharmacoeconomics. 2005;23:639-49.
31. Rovira J; Antoñanzas F. Economic analysis of health technologies and programmes. A Spanish Proposal for Methodological Standardisation. Pharmacoeconomics. 1995;8:245-52. Disponible en: http://www.farmacoeconomia.com/ Directrices/spespana.htm
32. Rovira J, Antoñanzas F. Estandarización de algunos aspectos metodológicos de los análisis coste/efectividad y coste/utilidad en la evaluación de tecnologías y programas sanitarios. En: Ministerio de Sanidad y Consumo, editores. Guías de práctica clínica e informes de evaluación. Madrid; 1994. p. 276-96.
33. Brüggenjürgen B, Selim D, Kardos P, Richter K, Vogelmeier C, Roll S, et al. Economic assessment of adjustable maintenance treatment with Budesonide/Formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics. 2005;23:723-73.
34. Migliaccio-Walle K, Caro JJ, Ishak KJ, O'Brien JA. Costs and medical care consequences associated with the diagnosis of peripheral arterial disease. Pharmacoeconomics. 2005;23:733-42.
35. Rubio-Terrés C, Domínguez-Gil A. Análisis farmacoeconómico del tratamiento de pacientes con exacerbación aguda de la bronquitis crónica con cefditoren pivoxilo o cefuroxima axetilo. Pharmacoeconomics - Spanish Research Articles. 2005;2:45-54.
36. Pradas R, Antoñanzas F, Zoellner Y. Evaluación económica de la vacunación antigripal por los servicios médicos de empresa: una perspectiva sanitaria. Pharmacoeconomics - Spanish Research Articles. 2005;2:55-63.
37. Relman A, Angell M. America's other drug problem: How the drug industry distorts Medicine and Politics. The New Republic. 2002;227:27-41.
38. Smith R. Medical journals are an extension of the marketing arm of Pharmaceutical companies. PLoS Med. 2005;2:138.
39. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al, International Committee of Medical Journal Editors. Editorial Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004;351:1250-1.
40. Sacristán JA, Hernández JM. Criteria for authorship. BMJ. 1995; 310:869-9.
41. Reinhardt UE. Making economic evaluations respectable. Soc Sci Med. 1997;45:555-62.
42. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.